Novartis' Daniel Vasella - CEO Pay

Novartis' Daniel VasellaDaniel Vasella - Novartis

Total Compensation: $15.1M

Details: Vasella's contract was set to end in 2008. By the fall, he had promoted vaccines and diagnostics chief, Joerg Reinhardt, to be COO. Rumors began flying that--with Reinhardt tapped to be Vasella's sucessor--the CEO was on his way out the door. But Vasella said he loved coming to work and felt an "emotional connection" to Novartis and a "deep desire" for the company to succeed. The love must have been mutual because not only did Vasella receive a hefty 21 percent raise in his 2008 compensation over 2007, the company extended his contract. Considering the company had chopped his pay by 33 percent in 2007, it's safe to say there's some love in the air once again.

Novartis News:
Vasella could go ... but he'll probably stay
Novartis to cut reps, reassign execs
Abbott, Novartis post double-digit profit hikes
Vasella: 'Teva is better than we are'
Novartis buys Protez, invests in vaccines
Vasella shaking up Novartis ops

Novartis' Daniel Vasella - CEO Pay
Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.